New report debunks idea of industry piggybacking on NIH
This article was originally published in Scrip
Executive Summary
In a new report, Manhattan Institute for Public Policy senior fellow Dr Benjamin Zycher, along with Joseph DiMasi and Christopher-Paul Milne, researchers at the Boston-based Tufts Center for the Study of Drug Development, attempt to answer sceptics of private industry who assert that drug companies get a “free ride” on government research, and that publiclyfunded medical research – not the industry itself – is by far the major source of innovative drugs.